- An eye drug biotech banks $118M and stocks its executive suite<figure><div><img src="https://imgproxy.divecdn.com/cIH1PfJposjsKezbbrmwTwtzNlhqTiIaZ_OaEGGTHE8/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjE5NzI0MTUxLmpwZ…BioPharma Dive · 4h ago↗ source
- The FDA was all in on AI. Will that change?<figure><div><img src="https://imgproxy.divecdn.com/SbY7pjJU5zpd9fYni9dr5J14qHlA98Kk2ofoQajpOLE/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9UVFIyNUguanBn.webp"/></div></figur…BioPharma Dive · 4h ago↗ source
- Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen optionsIncyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.Fierce Biotech